CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 8-K Event Material agreement · Other events
- 4 Open-market sale Director sold 201,725 shares at an average $87.04 ($17,558,774)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Director sold 4,513 shares at $85.43 ($385,546)
- 4 Open-market sale Director sold 342,962 shares at an average $85.96 ($29,482,338)
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Option exercise President and CEO acquired 25,937 shares (option exercise)
- 4 Grant or award Director acquired 4,955 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 4 Open-market sale Director sold 800 shares at $84.98 ($67,984)
- 4 Open-market sale Director sold 7,500 shares at an average $82.19 ($616,405)
- 4 Open-market sale President and CEO sold 38,209 shares at an average $83.64 ($3,195,661)
- 4 Open-market sale EVP, General Counsel sold 50,455 shares at an average $82.46 ($4,160,559)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 19 of 37 · 725 filings